Roche announced on Wednesday the launch of its cobas Cdiff Test, which detects Clostridium difficile in stool samples.
The test specifically targets the toxin B gene in the bacteria and provides information to assist doctors in treatment recommendations to further prevent infection in healthcare facilities.
The cobas Cdiff Test uses high assay sensitivity with rapid turnaround time and pre-analytic steps to enable earlier intervention for patients infected with C. difficile. Earlier intervention can lead to more effective infection control and prevent the spread of the bacteria.
"PCR methods for the detection of toxigenic strains of C. difficile have demonstrated sensitive performance" Frederic Barbut, head of the National Reference Laboratory for Clostridium difficile Hospital Saint-Antoine France, said. "Broad strain coverage and excellent analytical performance can have a positive impact on identifying C. difficile-associated diarrhea leading to improved patient management."
Head of Roche Molecular Diagnostics Paul Brown said the test offers a new tool for doctors to combat the hospital-acquired infection.
"When compared to other molecular methods the cobas Cdiff Test requires less sample handling and provides laboratories with a simplified workflow," Brown said. "It also delivers a lower inhibition rate which means fewer repeat samples and chances for error enabling better patient care."
The test uses the cobas 4800 System that offers the flexibility of scanning for causative agents of sexually transmitted infections and hospital-acquired infections in the same run on a single platform.